High-Dose Cytarabine Induction Regimens Elicit High Responses in Transplant-Eligible MCL
Published: Monday, Mar 23, 2020
Reid W. Merryman, MD
The addition of high-dose cytarabine to bendamustine and rituximab (Rituxan; BR) or rituximab were found to generate high response rates for transplant-eligible patients with mantle cell lymphoma (MCL), according to results of a pooled analysis that were published in Blood Advances.
... to read the full story